Home > Annual Financials > VENUS REMEDIES

VENUS REMEDIES Financial Statement Analysis
[BOM: 526953|NSE : VENUSREM]

The Revenues of VENUS REMEDIES have increased by 9.50% YoY .
The Earnings Per Share (EPS) of VENUS REMEDIES has decreased by -34.79 % YoY.
REVENUES
OPERATING MARGIN
PROFIT AFTER TAX
EPS
ROCE

VENUS REMEDIES Last 5 Annual Financial Results
[BOM: 526953|NSE : VENUSREM]

ConsolidatedMar2023
Mar2022
Mar2021
Mar2020
Mar2019
Revenues ₹600 Cr₹548 Cr₹339 Cr₹322 Cr₹372 Cr
Expenses ₹538 Cr₹494 Cr₹299 Cr₹289 Cr₹333 Cr
Operating Profit (Excl OI) ₹62 Cr₹54 Cr₹41 Cr₹33 Cr₹39 Cr
Other Income ₹8.31 Cr₹20 Cr₹5.31 Cr₹6.09 Cr₹2.39 Cr
Interest ₹0.48 Cr₹13 Cr₹13 Cr₹25 Cr₹36 Cr
Depreciation ₹34 Cr₹35 Cr₹32 Cr₹34 Cr₹34 Cr
Profit Before Tax ₹36 Cr₹49 Cr₹-8.04 Cr₹-30 Cr₹-28 Cr
Profit After Tax ₹41 Cr₹62 Cr₹-10.00 Cr₹-29 Cr₹-31 Cr
Consolidated Net Profit ₹41 Cr₹62 Cr₹-10.00 Cr₹-29 Cr₹-31 Cr
Earnings Per Share (Rs)₹19.87₹30.47₹50.04₹-8.10₹-23.15
PAT Margin (%)4.786.7911.27-2.95-8.88
ROE(%)5.909.8517.40-3.05-8.23
ROCE(%)7.757.8912.370.90-0.67
Total Debt/Equity(x)0.090.100.130.680.90

Key Financials

Market Cap : ₹ 448.5 Cr
Revenue (TTM) : ₹ 561.9 Cr
Net Profit(TTM) : ₹ 29.0 Cr
EPS (TTM) : ₹ 21.7
P/E (TTM) : 15.4

Industry Peers & Returns1W1M1Y
VENUS REMEDIES -4% -12.1% 89.2%
SUN PHARMACEUTICAL INDUSTRIES 3% 2.3% 68.2%
CIPLA 2.5% 0.4% 71.7%
DR REDDYS LABORATORIES -0.2% -4.9% 40.3%
ZYDUS LIFESCIENCES 5% 10.4% 109.1%
DIVIS LABORATORIES -1.6% -7% 23.8%
MANKIND PHARMA NA NA NA
TORRENT PHARMACEUTICALS 2.9% -2.2% 69%
LUPIN 2.8% 0% 147.8%


VENUS REMEDIES Revenues
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

9.50 %

5 Yr CAGR

12.67 %

Years Revenues % Change
Mar2023 ₹600 Cr
9.50
Mar2022 ₹548 Cr
61.53
Mar2021 ₹339 Cr
5.42
Mar2020 ₹322 Cr
-13.57
Mar2019 ₹372 Cr -


VENUS REMEDIES Operating Profit
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

15.50 %

5 Yr CAGR

12.00 %

Years Operating Profit % Change
Mar2023 ₹62 Cr
15.50
Mar2022 ₹54 Cr
31.75
Mar2021 ₹41 Cr
25.50
Mar2020 ₹33 Cr
-17.60
Mar2019 ₹39 Cr -

Operating Margins
Y-o-Y

5.50 %

5 Yr CAGR

-0.59 %

Years Operating Margin% % Change
Mar2023 10.35%
5.50
Mar2022 9.81%
-18.45
Mar2021 12.03%
19.11
Mar2020 10.1%
-4.72
Mar2019 10.6% -

VENUS REMEDIES Profit After Tax
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

-34.07 %

5 Yr CAGR

Positive

Years Profit After Tax % Change
Mar2023 ₹41 Cr
-34.07
Mar2022 ₹62 Cr
Positive
Mar2021 ₹-10.00 Cr
Negative
Mar2020 ₹-29 Cr
Negative
Mar2019 ₹-31 Cr -

PAT Margins
Y-o-Y

-29.60 %

5 Yr CAGR

Positive

Years PAT Margin(%) % Change
Mar2023 4.78 %
-29.60
Mar2022 6.79 %
-39.75
Mar2021 11.27 %
Positive
Mar2020 -2.95 %
Negative
Mar2019 -8.88 % -

VENUS REMEDIES Earnings Per Share (EPS)
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

-34.79 %

5 Yr CAGR

Positive

Years EPS % Change
Mar2023 ₹20
-34.79
Mar2022 ₹30
-39.11
Mar2021 ₹50
Positive
Mar2020 ₹-8.10
Negative
Mar2019 ₹-23 -

VENUS REMEDIES Return on Capital Employed (ROCE)
[BOM: 526953|NSE : VENUSREM]

Y-o-Y

-1.77 %

5 Yr CAGR

Positive

Years ROCE % Change
Mar2023 7.75%
-1.77
Mar2022 7.89%
-36.22
Mar2021 12.37%
1,274.44
Mar2020 0.9%
Positive
Mar2019 -0.67% -

VENUS REMEDIES Share Price vs Sensex

Current Share Price : ₹334.7
Current MarketCap: ₹ 448.5 Cr
Updated EOD on :Apr 18,2024

Share Price Returns(%) 1 Week 1 Month 1 Year
VENUS REMEDIES

-4%

-12.1%

89.2%

SENSEX

-2.9%

-0.4%

20%

VENUS REMEDIES related INDICES

No BSE index found!
No NSE index found

You may also like the below Video Courses


FAQ about VENUS REMEDIES Financials


How the annual revenues of VENUS REMEDIES have changed ?

The Revenues of VENUS REMEDIES have increased by 9.50% YoY .

How the Earnings per Share (EPS) of VENUS REMEDIES have changed?

The Earnings Per Share (EPS) of VENUS REMEDIES has decreased by -34.79 % YoY .